Artificial Intelligence (AI) In Biopharmaceuticals Market Growing Demand, Top Trends, Key Drivers, Companies And Forecast To 2033

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Artificial Intelligence (AI) In Biopharmaceuticals Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $4.99 Bn In 2028 At A CAGR Of 33.1% :

The artificial intelligence (AI) in biopharmaceuticals market size has grown exponentially in recent years. It will grow from $1.19 billion in 2023 to $1.59 billion in 2024 at a compound annual growth rate (CAGR) of 33.8%. The growth in the historic period can be attributed to advancements in computational power, biomedical data explosion, precision medicine paradigm, regulatory support and guidance.

The artificial intelligence (AI) in biopharmaceuticals market size is expected to see exponential growth in the next few years. It will grow to $4.99 billion in 2028 at a compound annual growth rate (CAGR) of 33.1%. The growth in the forecast period can be attributed to advancements in computational biology, integration of multi-modal data, convergence of ai and life sciences, regulatory support and frameworks, ethical and fair ai principles. Major trends in the forecast period include integration of multi-omics data, AI-driven drug design and discovery, explainable AI and regulatory acceptance, technological advancements, regulatory developments, and emerging opportunities.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=14251&type=smp

Artificial Intelligence (AI) In Biopharmaceuticals Market Major Segments
The artificial intelligence (AI) in biopharmaceuticals market covered in this report is segmented -

1) By Offering: Hardware, Software, Services
2) By Deployment: Cloud, On-Premises
3) By Technology: Machine Learning, Natural Language Processing, Deep Learning, Other Technologies
4) By Application: Business Process And Supply Chain, Drug Discovery, Medical Imaging And Diagnostics, Precision Medicine
5) By End-Users: Manufacturers, Contract Research Organizations, Academic And Government Research Institutes

Key Driver - Chronic Disease Prevalence Fueling Growth Of AI In Biopharmaceuticals Market

The growing prevalence of chronic diseases is expected to propel the growth of artificial intelligence (AI) in biopharmaceuticals market going forward. Chronic diseases are long-lasting conditions that generally progress slowly and may persist for years or even a lifetime. It arises from lifestyle factors, an aging population, genetic predispositions, and environmental factors. AI in biopharmaceuticals is increasingly used to manage chronic diseases because it analyzes large volumes of diverse data sources, identifies patterns, and personalizes treatment approaches. For instance, according to the National Library of Medicine, a US-based medical library, chronic diseases are expected to grow by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050. Therefore, the growing prevalence of chronic diseases drives the growth of artificial intelligence (AI) in the biopharmaceuticals market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=14251&type=smp

Prominent Trend - Advancements In AI-Powered Solutions For Drug Discovery And Precision Medicine

Major companies operating in artificial intelligence (AI) in biopharmaceuticals focus on developing innovative advancements such as target and lead identification suite AI-powered solutions to accelerate drug discovery and precision medicine to transform life sciences organizations. These solutions for drug discovery and precision medicine encompass a variety of innovative approaches to developing new drugs and tailoring treatments to individual patients. For instance, in May 2023, Google LLC, a US-based provider of cloud computing services, launched two new AI-powered tools called target and lead identification suites, designed to help researchers predict and understand the structure of proteins, which is a fundamental part of drug development. Additionally, this suite will help researchers ingest, store, analyze, and share mass amounts of genomic data, which is crucial for precision medicine. Also, these tools aim to streamline the drug discovery process, reduce costs, and bring new treatments to market faster. By providing efficient data management, accurate predictions of protein structures, and advanced genomic analysis capabilities, these tools aim to revolutionize drug development processes and improve patient outcomes.

Artificial Intelligence (AI) In Biopharmaceuticals Market Players
Major companies operating in the artificial intelligence (AI) in biopharmaceuticals market are Apple Inc., Google LLC, Microsoft Corporation, Tencent Holdings Limited, Amazon Web Services Inc., International Business Machines Corporation, Exscientia Limited, NVIDIA Corporation, Amgen Inc., DeepMind Technologies Limited, Schrödinger Inc., XtalPi Inc., ConcertAI Inc., Insilico Medicine Inc., Recursion Pharmaceuticals, BenevolentAI, BioXcel Therapeutics, Atomwise Inc., BioAge Labs Inc., GNS Healthcare, Berg Health, Deep 6 AI Inc., Cloud Pharmaceuticals Inc., Numerate Inc., AI Therapeutics, Envisagenics, twoXAR Inc., Cyclica Inc.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-biopharmaceuticals-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the artificial intelligence (AI) in biopharmaceuticals market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) in biopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Artificial Intelligence (AI) In Biopharmaceuticals Market Report Structure
3. Artificial Intelligence (AI) In Biopharmaceuticals Market Trends And Strategies
4. Artificial Intelligence (AI) In Biopharmaceuticals Market - Macro Economic Scenario
5. Artificial Intelligence (AI) In Biopharmaceuticals Market Size And Growth
…..
27. Artificial Intelligence (AI) In Biopharmaceuticals Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.